Oruka Therapeutics, Inc. (ORKA) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
15/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinORKA / S&P 94.03% / 15.20% |
LoseORKA / S&P ORKA unavailable / 15.00% |
LoseORKA / S&P ORKA unavailable / 50.40% |
| 2026-Q11/3 |
WinORKA / S&P 61.83% / -4.33% |
LoseORKA / S&P ORKA unavailable / 11.30% |
LoseORKA / S&P ORKA unavailable / 27.70% |
| 2025-Q41/3 |
WinORKA / S&P 57.62% / 2.65% |
LoseORKA / S&P ORKA unavailable / 9.00% |
LoseORKA / S&P ORKA unavailable / 13.40% |
| 2025-Q31/3 |
WinORKA / S&P 71.54% / 8.12% |
LoseORKA / S&P ORKA unavailable / 4.61% |
LoseORKA / S&P ORKA unavailable / 13.45% |
| 2025-Q20/3 |
LoseORKA / S&P 9.26% / 10.94% |
LoseORKA / S&P ORKA unavailable / 4.83% |
LoseORKA / S&P ORKA unavailable / 10.63% |
| 2025-Q10/3 |
LoseORKA / S&P -47.09% / -4.27% |
LoseORKA / S&P ORKA unavailable / 4.98% |
LoseORKA / S&P ORKA unavailable / 10.57% |
| 2024-Q40/3 |
LoseORKA / S&P -20.89% / 2.41% |
LoseORKA / S&P ORKA unavailable / 5.25% |
LoseORKA / S&P ORKA unavailable / 6.15% |
| 2024-Q31/3 |
LoseORKA / S&P -0.84% / 5.89% |
LoseORKA / S&P ORKA unavailable / 5.89% |
WinORKA / S&P 2235.14% / 6.11% |
| 2024-Q22/3 |
WinORKA / S&P 117.61% / 4.28% |
LoseORKA / S&P ORKA unavailable / 5.38% |
WinORKA / S&P 1593.02% / 5.12% |
| 2024-Q10/3 |
LoseORKA / S&P 3.53% / 10.56% |
LoseORKA / S&P ORKA unavailable / 5.71% |
LoseORKA / S&P -23.64% / 5.59% |
| 2023-Q40/3 |
LoseORKA / S&P -15.42% / 11.69% |
LoseORKA / S&P ORKA unavailable / 6.81% |
LoseORKA / S&P -46.38% / 7.78% |
| 2023-Q31/3 |
WinORKA / S&P -0.99% / -3.27% |
LoseORKA / S&P ORKA unavailable / 7.52% |
LoseORKA / S&P -63.37% / -5.03% |
| 2023-Q20/3 |
LoseORKA / S&P 2.01% / 8.74% |
LoseORKA / S&P ORKA unavailable / 9.50% |
LoseORKA / S&P -63.56% / -8.57% |
| 2023-Q10/3 |
LoseORKA / S&P -16.03% / 7.50% |
LoseORKA / S&P ORKA unavailable / 10.77% |
LoseORKA / S&P -57.69% / -15.69% |
| 2022-Q41/3 |
WinORKA / S&P 15.05% / 7.56% |
LoseORKA / S&P ORKA unavailable / 11.88% |
LoseORKA / S&P ORKA unavailable / -17.99% |
| 2022-Q30/3 |
LoseORKA / S&P -17.27% / -4.88% |
LoseORKA / S&P ORKA unavailable / 13.47% |
LoseORKA / S&P ORKA unavailable / -1.41% |
| 2022-Q21/3 |
WinORKA / S&P 8.26% / -16.10% |
LoseORKA / S&P ORKA unavailable / 13.71% |
LoseORKA / S&P ORKA unavailable / 11.04% |
| 2022-Q11/3 |
WinORKA / S&P 6.98% / -4.60% |
LoseORKA / S&P ORKA unavailable / 15.97% |
LoseORKA / S&P ORKA unavailable / 42.23% |
| 2021-Q40/3 |
LoseORKA / S&P -27.36% / 11.03% |
LoseORKA / S&P ORKA unavailable / 15.00% |
LoseORKA / S&P ORKA unavailable / 96.40% |
| 2021-Q30/3 |
LoseORKA / S&P -15.19% / 0.58% |
LoseORKA / S&P ORKA unavailable / 10.77% |
LoseORKA / S&P ORKA unavailable / 69.42% |
| 2021-Q20/3 |
LoseORKA / S&P -4.38% / 8.55% |
LoseORKA / S&P ORKA unavailable / 6.58% |
LoseORKA / S&P ORKA unavailable / 51.81% |
| 2021-Q10/3 |
LoseORKA / S&P -8.98% / 6.17% |
LoseORKA / S&P ORKA unavailable / -1.06% |
LoseORKA / S&P ORKA unavailable / 7.39% |
| 2020-Q40/3 |
LoseORKA / S&P -9.28% / 12.15% |
LoseORKA / S&P ORKA unavailable / -3.72% |
LoseORKA / S&P ORKA unavailable / -33.42% |
| 2020-Q30/3 |
LoseORKA / S&P -33.23% / 8.93% |
LoseORKA / S&P ORKA unavailable / -2.04% |
LoseORKA / S&P ORKA unavailable / -27.10% |
| 2020-Q21/3 |
WinORKA / S&P 137.28% / 20.54% |
LoseORKA / S&P ORKA unavailable / -0.46% |
LoseORKA / S&P ORKA unavailable / -27.11% |
| 2020-Q10/3 |
LoseORKA / S&P -51.14% / -19.60% |
LoseORKA / S&P ORKA unavailable / 3.47% |
LoseORKA / S&P ORKA unavailable / -14.75% |
| 2019-Q40/3 |
LoseORKA / S&P 6.73% / 9.07% |
LoseORKA / S&P ORKA unavailable / 5.36% |
LoseORKA / S&P ORKA unavailable / 2.99% |
| 2019-Q30/3 |
LoseORKA / S&P -26.91% / 1.70% |
LoseORKA / S&P ORKA unavailable / 5.02% |
LoseORKA / S&P ORKA unavailable / 0.21% |
| 2019-Q21/3 |
WinORKA / S&P 9.91% / 4.30% |
LoseORKA / S&P ORKA unavailable / 6.64% |
LoseORKA / S&P ORKA unavailable / 8.65% |
| 2019-Q10/3 |
LoseORKA / S&P 12.12% / 13.65% |
LoseORKA / S&P ORKA unavailable / 8.12% |
LoseORKA / S&P ORKA unavailable / 14.29% |
| 2018-Q40/3 |
LoseORKA / S&P -41.07% / -13.52% |
LoseORKA / S&P ORKA unavailable / 9.05% |
LoseORKA / S&P ORKA unavailable / 18.23% |
| 2018-Q30/3 |
LoseORKA / S&P 0.00% / 7.71% |
LoseORKA / S&P ORKA unavailable / 10.21% |
LoseORKA / S&P ORKA unavailable / 19.06% |
| 2018-Q21/3 |
WinORKA / S&P 12.00% / 3.43% |
LoseORKA / S&P ORKA unavailable / 9.03% |
LoseORKA / S&P ORKA unavailable / 14.46% |
| 2018-Q10/3 |
LoseORKA / S&P -62.96% / -0.76% |
LoseORKA / S&P ORKA unavailable / 7.68% |
LoseORKA / S&P ORKA unavailable / 12.46% |
| 2017-Q41/3 |
WinORKA / S&P 17.39% / 6.64% |
LoseORKA / S&P ORKA unavailable / 7.03% |
LoseORKA / S&P ORKA unavailable / 13.82% |
| 2017-Q30/3 |
LoseORKA / S&P -52.08% / 4.48% |
LoseORKA / S&P ORKA unavailable / 5.68% |
LoseORKA / S&P ORKA unavailable / 17.57% |
| 2017-Q20/3 |
LoseORKA / S&P -5.88% / 3.09% |
LoseORKA / S&P ORKA unavailable / 4.83% |
LoseORKA / S&P ORKA unavailable / 17.74% |
| 2017-Q10/3 |
LoseORKA / S&P -10.53% / 6.07% |
LoseORKA / S&P ORKA unavailable / 3.67% |
LoseORKA / S&P ORKA unavailable / 13.32% |
| 2016-Q40/3 |
LoseORKA / S&P 0.71% / 3.82% |
LoseORKA / S&P ORKA unavailable / 2.09% |
LoseORKA / S&P ORKA unavailable / 7.05% |
| 2016-Q30/3 |
LoseORKA / S&P -2.41% / 3.85% |
LoseORKA / S&P ORKA unavailable / 0.20% |
LoseORKA / S&P ORKA unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ORKA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 552.30% | 20.78% |
| Annualized return | 552.30% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ORKA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 388.84% | 83.14% |
| Annualized return | 37.35% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | ORKA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -70.74% | 319.30% |
| Annualized return | -11.56% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |